Slides
Page 1
NASDAQ: SNTI | sentibio.com Corporate Presentation September 2025
Page 2
Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “future,” “objective,” “opportunity,” “potential,” “proposed,” “targets,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding attributes and benefits of our technology platform and of our product candidates, including their therapeutic potential; our cash runway; clinical trials, including trial design and endpoints, our ability to achieve such endpoints, our plans to transition our Phase 1 clinical trial of SNTI-202 to a pivotal study and our manufacturing process and its potential benefits, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Many actual events and circumstances are difficult or impossible to predict, are beyond our control and will differ from assumptions. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risk that results observed in studies of our product candidates, including preclinical studies and future clinical trials of any of our product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk that we may cease or delay clinical development of any of our product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in subject enrollment and continuation in current and planned clinical trials, difficulties in manufacturing or supplying our product candidates for preclinical and clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), our ability to obtain, maintain and protect our intellectual property, our dependence on third parties for development and manufacture of product candidates, our ability to manage expenses and to obtain additional funding when needed to support our business activities and establish and maintain strategic business alliances and new business initiatives, the impacts of macroeconomic and geopolitical events, including various global conflicts, increasing rates of inflation and rising interest rates on business operations and expenses, and the risk that our product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, as well as those set forth in the section titled “Risk Factors” of Senti Bio’s most recently filed periodic report, and other documents filed by Senti Bio from time to time with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Trademarks This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this presentation may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that the applicable owner will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other entities’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entities. 2
Page 3
Investment Highlights 3*CR: Complete Remission • Orphan Drug Designation granted June 2025 • Demonstrated positive preliminary efficacy data in ongoing Phase 1 trial for treatment in R/R AML • Dose finding completed, CR* and durability data presented at AACR 2025 along with correlative data supporting Logic Gating mechanism of action Additional Phase 1 Data to be Reported by 4Q25 Potential best-in-class Logic-Gated cell therapy pipeline, initially targeting AML Lead program SENTI-202 First-in-Class Off-the-Shelf Logic-Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy Investment from Leading Healthcare Institutional Investors Pipeline of Logic-Gated NK and T cells for hard-to-treat cancers Gene Circuits platform provides blockbuster opportunity to selectively and effectively target liquid and solid tumors while sparing healthy cells Scalable off-the-shelf manufacturing process streamlines treatment
Page 4
Programming Gene Circuits to Enhance the Potential of Cell and Gene Therapies SENTI BIO CONFIDENTIAL, #CT014 4 Engineering Cells with DNA-Encoded Programs, Enabling Them to Sense Inputs, Compute Decisions, and Respond to Disease Multi-Arming Regulator Dial Smart SensorLogic Gating Sense diseased vs healthy cells (e.g., SENTI-202) Stimulate immune cells, overcome TME, promote NK cell function Dial payload expression up/down Cell/disease-specific promoters Therapeutic transgene expressed Gene Circuits 4
Page 5
Logic Gates in Cell Therapy 5 Enable CAR-NK / CAR-T Cells to Address Broad Liquid and Solid Tumor Applications *ADC: antibody drug conjugate; TCE: T cell engagers Cancer Cells Healthy Cells Commercially approved CAR T cell therapies Recognize Single Antigen Target Single Antigen Target may be found on both cancer and healthy cells KILL KILL Biologics (ADC/TCE)* Non-Logic Gate Approaches Senti Bio’s Logic Gate Approach Cancer Cells Healthy Cells SENTI-202 and Other Undisclosed Programs KILL PROTECT (DO NOT KILL) OR Gate (aCAR) Kill if you see Antigens CD33 or FLT3 NOT Gate (iCAR) Do Not Kill if you see Antigen EMCN even if you see CD33 or FLT3 Recognizes Multiple Antigen Targets
Page 6
Product Candidates Target Application Discovery Preclinical Early Stage Clinical Late Stage Clinical Highlights SENTI-202 CD33 OR FLT3 NOT EMCN AML, MDS and Other Blood Cancers Positive preliminary AML data presented at AACR 2025, including correlative data from patients supporting Logic Gate mechanism of action Undisclosed Undisclosed Solid Tumors Provides multiple pipeline expansion opportunities Potentially Best-in-Class Logic-Gated Cell Therapy Pipeline 6 Gene Circuits Platform has Ability to Effectively and Selectively Target Liquid and Solid Tumors
Page 7
SENTI-202 Targets a Multi-Billion Dollar Opportunity in AML 7 • 20,800 newly diagnosed AML patients in US every year1 • ~60% patients experience relapse or death within 12 months2 AML Estimated Disease Burden Relapsed/Refractory AML Patient Outcome Effective Anti-AML Therapies Need To: • Current standard of care responses4,5 • CR rate ~15-25% • CR/CRh rate ~20-33% Median survival of 5.3 months3 5-year survival rate is 12.6%3 Target heterogenous clones / leukemic stem cells (LSCs)6 Selectively kill AML blasts and LSCs, and spare HSCs To achieve deep / MRD negative CR Leading to durable remissions / longer survival4,6 To support normal blood cell count recovery Leading to improved prognosis / longer survival7 1 2 CR: complete remission; CRh: complete remission with partial hematologic recovery; MRD: measurable residual disease; HSC: hematopoietic stem cell 1SEER 2024; 2Tenold Frontiers in Oncology 2021; 3Brandwein AJBR 2020; 4Dohner Blood 2022; 5USPI Idhifa, Xospata, Tibsovo; 6Zeijlemaker Leukemia 2019; 7Innes Blood 2018
Page 8
SENTI-202: Intelligently Designed CAR-NK May Overcome Limitations of Current Therapies Against AML 8LSC: Leukemic stem cells; HSC: hematopoietic stem cell; HSPC: hematopoietic stem and progenitor cell Bivalent CD33 and/or FLT3 activating CAR Calibrated release IL- 15 Endomucin inhibitory CAR to protect healthy cells Persistence, activation of CAR-NK and immune cells Healthy NK cells from selected adult donors FLT3 EMCN CD33 Healthy cell protection HSC aCAR iCAR Host immune cell SENTI-202 Cancer cell killing Blast cell CD33 LSC FLT3 SENTI-202 Gene Circuit Design • OR Logic Gate “Kills” leukemia blasts and LSCs via CD33 OR FLT3 activating CAR (aCAR) • CD33 and/or FLT3 expressed in ~95% of AML patients with CD33 being predominantly expressed on bulk blasts and FLT3 on LSCs • NOT Logic Gate “Protects” healthy HSC/HSPCs from ‘off-tumor, on-target’ effects • Protection of HSC/HSPCs via Endomucin (EMCN) inhibitory CAR (iCAR), even when they express CD33 and/or FLT3 • EMCN found predominantly on healthy HSC/HSPC surface, rarely on AML blasts • Calibrated release IL-15 “Enhances” SENTI-202 and host immune cell activity and persistence SENTI-202 is designed to selectively kill both AML blasts and LSCs while protecting healthy HSC/HSPCs using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit
Page 9
SENTI-202 Scalable Manufacturing Process Off-the-Shelf Allogeneic CAR-NK 9 Lenti virus Outpatient use potential Isolate from selected donors Thaw and Infuse Off-the-Shelf Scalable Process NK Cells Selected Donors Engineer Cryopreserve and Store Expand SENTI-202 Gene Circuit delivered through single transduction step 1 2 3 4 1 Easy to thaw vials Final product harvested and cryopreserved NK cells isolated from peripheral blood of selected donors NK cells efficiently engineered with Gene Circuits High post- thaw potency Gene Circuit Engineered CAR- NK cells Patient aCAR iCAR SENTI-202
Page 10
• Primary objective- safety and determination of MTD/RP2D • Efficacy, including bone marrow recovery and MRD • Pharmacokinetics, pharmacodynamics, CyTOF SENTI-202: Ongoing Phase 1 Trial (SENTI-202-101) Design • Adult patients age ≥18 and <75 years • R/R CD33 and/or FLT3 expressing heme malignancies including AML/MDS • Received 1-3 2 prior AML treatments including targeted agents if applicable • “3+3” study design • Dose finding followed by AML, MDS and other expansion cohorts at RP2D • Two dose levels, two dose schedules • No DLTs, MTD not reached, preliminary RP2D identified- Schedule I, dose level 2 Study Design Key Endpoints 1 28Day -7 to -3 0 7 14 SENTI-202 Dose Schedule Efficacy Assessment Multiple cycles allowed to achieve optimal response3 Multi-Dose Cycle in Multicenter, Multinational, Open-Label Study Lymphodepletion Flu/Ara-C 28Day -7 to -3 0 3 7 10 14 Dose Schedule I Schedule II Dose Level CAR+ NK Cells/Dose 1 1 x 109 2 1.5 x 109 SENTI-202 Dose DLT: dose limiting toxicity; MRD: measurable residual disease; R/R: relapsed refractory; RP2D: recommended phase 2 dose 1 NCT06325748; 2 1-2 prior for MDS; 3 Subjects in MRD negative complete remission may receive one additional cycle as consolidat ion Response and Durability Data Presented at AACR 2025 10 Patient Population
Page 11
Study Enrolled a High-Risk R/R AML Population with Multiple Baseline Adverse Characteristics 11Data from an open clinical database of an ongoing study as of 7 Apr 2025; * Primary refractory defined as failure to achieve cCR or cCR lasting <3 mo with front-line therapy • Median of <1 yr from diagnosis to trial entry across all patients and in preliminary RP2D cohort • Majority of patients (all in preliminary RP2D cohort) with adverse risk genetics by ELN 2022 criteria • All patients with previous chemotherapy exposure including fludarabine and/or cytarabine (4 received both) and majority with previous venetoclax exposure preliminary RP2D Baseline Characteristics Dose Level 1 Dose Level 2 All Patients N = 9Schedule I N = 3 Schedule II N = 3 Schedule I N = 3 Age, yr, median (range) 64 (26,72) 41 (36, 67) 63 (51, 69) 63 (26, 72) Male, n (%) 1 (33) 2 (67) 3 (100) 6 (67) Years from AML diagnosis, median (range) 2.84 (0.5, 6.2) 0.49 (0.3, 0.8) 0.94 (0.5, 1.0) 0.75 (0.3, 6.2) Number of prior lines, median (range) 1 (1,1) 2 (1, 2) 2 (2, 3) 2 (1,3) Fludarabine and/or Ara-C, n (%) 3 (100) 3 (100) 3 (100) 9 (100) Venetoclax, n (%) 1 (33) 3 (100) 3 (100) 7 (78) Bone marrow transplant, n (%) 1 (33) 0 (0) 1 (33) 2 (22) Primary refractory* , n (%) 1 (33) 2 (67) 2 (67) 5 (56) Adverse risk by ELN 2022, n (%) 2 (67) 2 (67) 3 (100) 7 (78) Baseline bone marrow blasts, %, median (range) 20 (15, 69) 30 (18, 31) 45 (10, 93) 30 (10, 93) Baseline platelet count < 50 x 109/L , n (%) 0 (0) 2 (67) 2 (67) 4 (44)
Page 12
Preliminary Safety Data Indicate that SENTI-202 is Well Tolerated AEIs: treatment emergent adverse events of interest includes adverse events with onset after SENTI-202 dosing and within 30 days of last dose of study treatment; Grading per CTCAE v5.0; Data from an open clinical database of an ongoing study as of 7 Apr 2025 12 preliminary RP2D Any Grade 3-4* AEs Regardless of Relationship Dose Level 1 Dose Level 2 All Patients N = 9Schedule I N = 3 Schedule II N = 3 Schedule I N = 3 Any Grade ≥ 3 AEs, n (%) 3 (100) 3 (100) 3 (100) ^ 9 (100) Febrile Neutropenia 1 (33) 1 (33) 2 (67) ^ 4 (44) Platelet Count Decreased 2 (67) 0 2 (67) ^ 4 (44) Anemia 1 (33) 1 (33) 0 2 (22) Abdominal Pain 1 (33) 1 (33) 0 2 (22) *No Grade 5 AEs, ^ 1 patient with G3 febrile neutropenia and G4 platelet count decreased assessed as possibly related to SENTI -202 • No significant difference in AE profile across dose cohorts • SENTI-202 related AEIs in > 1 patient were Grade 1 pyrexia with either chills, hypotension or hypoxia reported as Grade 1/2 CRS that resolved rapidly with standard of care and likely represent delayed infusion related reactions. SENTI-202 was well tolerated • In general, G3-4 AEs on study were hematologic, unrelated to SENTI-202 and consistent with R/R AML patients receiving LD • No single type of SAE reported in > 1 patient
Page 13
Responses Observed Across All Dose Cohorts Data from an open clinical database of an ongoing study as of 7 Apr 2025 13 preliminary RP2D Best Overall Response on Study, n (%) Dose Level 1 Dose Level 2 All Patients N = 7*Schedule I N = 3 Schedule II N = 1* Schedule I N = 3 Overall Response Rate (ORR) 2 (67) 1 (100) 2 (67) 5 (71) composite CR Rate (cCR)^ 2 (67) 0 2 (67) 4 (57) Negative MRD Status in cCR Patients 2/2 (100) N/A 2/2 (100) 4/4 (100) Response Category, n(%) CR 2 (100) 0 1 (33) 3 (43) CRh 0 0 1 (33) 1 (14) MLFS 0 1 (100) 0 1 (14) SD 0 0 1 (33) 1 (14) PD 1 (33) 0 0 1 (14) *Two patients continuing into second Cycle after achieving SD with blast reduction from 31% to 13% and 5% to 3% respectively are excluded from best overall response assessment; ^CR + CRh + CRi AML Response • 5 of 7 patients overall achieved ORR • 2/3 and 4/7 patients achieved cCR respectively in preliminary RP2D cohort and all patients • 4/4 cCR patients were MRD- • All cCR responses are ongoing as of data-cut with median duration of response not reached
Page 14
Rapid Bone-Marrow Blast Reduction Observed Across All Dose Cohorts 14Data from an open clinical database of an ongoing study as of 7 Apr 2025 Blast Reduction Noted in Majority of Patients Across All Dose Cohorts * End of cycle 1 for patients 8 and 9
Page 15
Early Deep Responses Noted Across Dose Levels with Durability 8+ Months I0 Ref: Primary refractory defined as failure to achieve cCR or cCR lasting <3 mo with front-line therapy; Adv. Risk: Adverse Risk genetics by ELN 2022; FA Exp: fludarabine and/or Ara-C Exposed, both indicates exposed to both agents; FA Ref: Fludarabine and/or Ara-C refractory (failure to achieve cCR or cCR lasting < 3 mo), both indicates refractory to both agents; #Patient had detectable IDH2 mutation by NGS while in morphologic remission and started on venetoclax/enasidenib; Data from an open clinical database of an ongoing study as of 7 Apr 2025 15 preliminary RP2D 0 30 60 90 120 150 180 210 CR MRD-* CR MRD+ # 5+ mo. CR CRh MRD+* CRh MRD-* HCT 4+ mo. CR SD No response ^Cycle1 ^^ Cycle 2 ^ ^^ ^ Days 0 30 60 90 120 150 180 210 240 270 300 330 360 SD SD PR CR MRD -** HCT 8+ mo. CR CR MRD-* HCT 7+ mo. CR PD Death MLFS MRD+* PD ^ Cycle 1 ^^ Cycle 2 ^ ^^ ^ ^^ ^ ^^ ^ ^ Days *MRD by multi-parametric flow (sensitivity ≤ 1/10-4), **MRD by NGS (sensitivity ≤ 1/10-2) Pt I0 Ref Adv. Risk FA Exp FA Ref Pt1 No Yes Yes No Pt2 No No Yes No Pt3 Yes Yes Yes Yes Pt7 Yes No Yes- both Yes- both Pt8 Yes Yes Yes Yes Pt9 Unk Yes Yes- both Unk Pt I0 Ref Adv. Risk FA Exp FA Ref Pt4 Yes Yes Yes- both Yes- both Pt5 No Yes Yes- both No Pt6 Yes Yes Yes Yes
Page 16
CyTOF Bone Marrow Data Reveals SENTI-202 Treatment Results in Decreased LSCs in Responders IdU: 5-Iodo-2’-Deoxyuridine; Data from an open clinical database of an ongoing study as of 7 Apr 2025 16 LSC (CD34+ CD38low) in Bone Marrow % CD34+ CD38low LSC of AML cells LSCs in bone marrow at baseline are largely non-cycling when analyzed by Ki67 and IdU • CyTOF measured 49 different proteins in serial bone marrow derived mononuclear cells samples from baseline and end of each Cycle • At baseline, majority of leukemic stem cells (LSCs) were in G0 phase and not expected to be susceptible to chemotherapy • With SENTI-202 treatment, LSCs decreased > 10-fold in all patients who achieved cCR * Patient 5 CyTOF samples had low viability overall * 100 10 1 0.1 0.01 0 Baseline C1D28 C2D28
Page 17
Rapid Normalization of Peripheral Blood Cell Count Along with Protection of BM HSPCs in Patients Who Achieved cCR 17Data from an open clinical database of an ongoing study as of 7 Apr 2025 Peripheral Blood Cell Counts Rapid blood cell count recovery in periphery in patients who achieved cCR • Median of 21 days for neutrophil count ≥ 0.5 and 1 x109/ L, and 28/35 days to platelet count ≥ 50 and 100 x109/ L • CyTOF analyses revealed HSPCs were maintained or increased in bone marrow of patients who achieved cCR consistent with SENTI-202 Logic Gate mechanism of action HSPC (CD34+ CD38low) in Bone Marrow (BM) %CD34+ CD38low HSPC of all cells 0 1 2 3 4 5 6 0 100 200 300 400 500 600 -7 0 7 14 21 28 Absolute Neutrophil Count (x 109/ L) Platelet Count (x 109/ L) Days 0.001 0.1 1 10 0.01 100 Baseline C1D28 C2D28 * * Patient 5 CyTOF samples had low viability overall Threshold for CR
Page 18
SENTI-202 Is Detected in Periphery of All Treated Patients Consistent with Allo-NK Profile Interim PK data as of 7 Apr 2025; value of 1 assigned for timepoints with non-measurable transgene, LLOQ estimated using equivalent DNA loading and is the lower limit of quantitation 18 • PK profile consistent with allogeneic NK cell therapy • Modest peripheral expansion in first 14 days consistent with NK biology and safety of SENTI-202 • Clearance >14 days from periphery • No significant difference in exposure across patients who achieved cCR or not • No significant difference in exposure across Dose Cohorts • No significant difference in exposure between Cycle 1 and 2 Cycle 1 LLOQ Copies/μg DNA Time (Days) 0 100 1000 10,000 7 14 21 28 0 100 1000 7 14 21 28 LLOQ 10,000 Cycle 2
Page 19
Promising SENTI-202 Preliminary Results in Multi-Billion Dollar AML Opportunity • SENTI-202-101 trial enrolled heavily treated R/R AML patients with poor prognosis • 5/7 ORR and 4/7 cCR across all patients including 2/3 cCR in preliminary RP2D cohort • 4/4 cCR MRD- as assessed per local standard of care • All cCR patients maintaining morphologic remission with 4+ to 8+ months durability and ongoing • SENTI-202 detected in all treated patients, consistent with other allogeneic CAR NK cell therapy PK profiles • Modest peripheral expansion in first 14 days consistent with NK biology and safety profile of SENTI-202 • SENTI-202 treatment decreased LSC frequencies in patients achieving cCR • SENTI-202 maintained (or increased) healthy HSPC in patients achieving cCR frequencies • These findings are consistent with SENTI-202 Logic Gated gene circuit’s designed mechanism of action Response and Durability Data Presented at AACR 2025 • SENTI-202 was well tolerated with potential for outpatient use • In general, G3-4 AEs on study were hematologic, unrelated to SENTI-202 and consistent with R/R AML patients receiving LD • No single type of SAE reported in > 1 patient • No significant difference in AE profile across dose cohorts • No DLTs, MTD not reached • Preliminary RP2D defined 19 Efficacy and Durability CyTOF Analyses of BM Pharmacokinetics Safety
Page 20
Logic Gate Technology Could Expand Addressable Cancer Indications, Particularly in Solid Tumors1,2 • Conventional ADCs, TCEs, and cell therapies depend on clean single targets, and are ill-suited to address heterogeneity inherent in many cancers and on-target off-tumor toxicity • Senti’s Logic Gate technology enables cell therapies that can potentially overcome cancer heterogeneity and reduce on- target off-tumor toxicity ADC: antibody-drug conjugate; TCE: T-cell engager; 1. Kwon Nature 2023; 2. Dannenfelser Cell Systems 2020; 3. Solid tumors market estimated to reach US$ 375.4 billion by 2034, impelled by widespread adoption of targeted therapy. BioSpace. (2024, July 19) Total Solid Tumor Market $375 Billion By 2034 Solid Tumors With Clean Single Target ADC TCE Cell Therapy Senti’s Logic Gated Cell Therapies 20
Page 21
Platform Enables Rapid Optimization of Highly Potent & Protective Logic Gates in NK Cells for Solid Tumors 21 CEA NOT VSIG2 CAR-NK cells spared VSIG2-expressing model healthy cells while maintaining robust on-target, on-tumor killing of CEA+ cancer cells No NK Cells CEA CAR-NK Cells CEA NOT VSIG2 CAR-NK Cells Precise killing of cancer cells while sparing healthy cells Significant killing of both cancer and healthy cells No killing of cancer or healthy cells Model healthy cells (VSIG2+CEA+)Cancer cells (VSIG2‒CEA+)
Page 22
Platform Enables Rapid Optimization of Highly Potent & Protective Logic Gates in T Cells for Solid Tumors 22 CEA NOT VSIG2 CAR-T cells spared VSIG2-expressing model healthy cells while maintaining robust on-target, on-tumor killing of CEA+ cancer cells No T Cells CEA CAR-T Cells CEA NOT VSIG2 CAR-T Cells Precise killing of cancer cells while sparing healthy cells Significant killing of both cancer and healthy cells No killing of cancer or healthy cells Model healthy cells (VSIG2+CEA+)Cancer cells (VSIG2‒CEA+)
Page 23
23 Corporate Overview
Page 24
Investment Summary Investment from Leading Healthcare Institutional Investors Gene Circuits platform has ability to selectively target liquid and solid tumors Potential best-in-class Logic-Gated cell therapy Pipeline initially targeting AML Dose finding completed, preliminary RP2D determined Demonstrated positive preliminary CR and durability data in patients with R/R AML as presented at AACR 2025 Lead program SENTI-202 First-in-Class Off-the-Shelf Logic-Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy 24
Page 25
Industry-Leading Management with Top-Tier Board Tim Lu, MD, PhD CEO and Co-founder Jay Cross CFO Kanya Rajangam, MD, PhD President, Head of R&D and CMO Rob Cutler, JD SVP , Head of Legal Affairs Amy Alford VP , R&D Operations Thomas Chung VP , Strategic Finance and Corporate Development Brian Garrison, PhD VP , Research and Translational Science Dee Olomajeye Dragon SVP , People & Culture Strategy and Head of Administrative Operations Board Experience James Collins, PhD Scientific Co-Founder, MIT Brenda Cooperstone, MD Pfizer Rare Disease Feng Hsiung Acion Partners Tim Lu, MD, PhD CEO & Co-Founder Ed Mathers NEA Fran Schulz Ernst & Young Donald Tang Celadon Partners Bryan Baum K5 Global Faraz Siddiqui SVP , Technical Operations 25
Page 26
NASDAQ: SNTI | sentibio.com Investor Relations JTC Team snti@jtcir.com Thank You!